You are here

Article Text

Article menu

other Versions

Download PDFPDF
Letter
Abatacept in relapsing polychondritis
  1. Guillaume Moulis1,2,3,
  2. Grégory Pugnet1,2,3,
  3. Laurent Sailler1,2,3,
  4. Leonardo Astudillo1,2,
  5. Philippe Arlet1,2
  1. 1Service de Médecine Interne, CHU Toulouse, Toulouse, France
  2. 2Université de Toulouse, Toulouse, France
  3. 3Inserm, UMR1027, Toulouse, France
  1. Correspondence to Dr Guillaume Moulis, Service de Médecine Interne, salle le Tallec, CHU Purpan, place du Dr Baylac, 31059 Toulouse cedex9 , France; guillaume.moulis{at}univ-tlse3.fr

https://doi.org/10.1136/annrheumdis-2013-204336

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Dear Editor,

    We read with great interest the open clinical trial of four relapsing polychondritis (RP) patients treated with abatacept by Peng and Rodriguez recently published in the Annals of the Rheumatic Diseases.1 Indeed, as the authors pointed out, there is rational to block T-cell pathway in this disease, though the biologic agents most used as second-line therapy after corticosteroids (CS) are proinflammatory cytokines blockers as tumor necrosis factor (TNF) inhibitors or tocilizumab.2 Of note, rituximab seems not efficient in this disease.3

    Despite this rational, the study by Peng and Rodriguez is the first report of abatacept use in RP since we reported a first case in 2010.4 Results from this nice small clinical trial using abatacept subcutaneously at the dose of 125 mg weekly are mitigated: three patients experienced a considerable improvement on ear, nose and throat (ENT) …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles